Communiqués Protalix BioTherapeutics, Inc.

Actions

PLX

US74365A3095

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:00:00 26/06/2026			Varia. 5j.	Varia. 1 janv.
2,300 ^USD	+3,60 %		+3,60 %	+27,78 %

13/05	Transcript : Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
13/05	Protalix BioTherapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

13/05	Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)	PU
13/05	Protalix: Q1 Earnings Snapshot	AQ
13/05	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results	PR
06/05	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026	PR
18/03	Protalix: Q4 Earnings Snapshot	AQ
18/03	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results	PR
11/03	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026	PR
09/03	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)	AQ
11/02	Protalix BioTherapeutics : PLX Corporate Presentation (February 2026)	PU
30/01	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU	AQ
05/01	Protalix BioTherapeutics Letter to Stockholders	PR
17/12	Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement	PR
18/11	Protalix BioTherapeutics : PLX Corporate Presentation (November 2025)	PU
13/11	Protalix: Q3 Earnings Snapshot	AQ
13/11	Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results	PR
06/11	Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025	PR
03/11	Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU	AQ
24/10/25	Protalix BioTherapeutics : PLX Corporate Presentation (October 2025)	PU
17/10/25	Protalix BioTherapeutics : PLX Corporate Presentation (October 2025)	PU
17/10/25	Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU	AQ
02/09/25	Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	PR
01/09/25	Protalix BioTherapeutics : PLX Corporate Presentation (August 2025)	PU
14/08/25	Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results	PR
07/08/25	Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025	PR
21/07/25	Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer	PR